Pdcd4 (programmed cell death protein 4) is an important novel tumour suppressor inhibiting transformation, translation, invasion and intravasation, and its expression is down-regulated in several cancers. However, little is known about the transcriptional regulation and the promoter of this important tumour suppressor. So far the following is the first comprehensive study to describe the regulation of Pdcd4 transcription by ZBP-89 (zinc-finger-binding protein 89), besides characterizing the gene promoter. We identified the transcriptional start sites of the human pdcd4 promoter, a functional CCAAT-box, and the basal promoter region. Within this basal region, computer-based analysis revealed several potential binding sites for ZBPs, especially for Sp (specificity protein) family members and ZBP-89. We identified four Sp1/Sp3/Sp4-binding elements to be indispensable for basal promoter activity. However, overexpression of Sp1 and Sp3 was not sufficient to enhance Pdcd4 protein expression. Analysis in different solid cancer cell lines showed a significant correlation between pdcd4 and zbp-89 mRNA amounts. In contrast with Sp transcription factors, overexpression of ZBP-89 led to an enhanced expression of Pdcd4 mRNA and protein. Additionally, specific knockdown of ZBP-89 resulted in a decreased pdcd4 gene expression. Reporter gene analysis showed a significant up-regulation of basal promoter activity by co-transfection with ZBP-89, which could be abolished by mithramycin treatment. Predicted binding of ZBP-89 to the basal promoter was confirmed by EMSA (electrophoretic mobility-shift assay) data and supershift analysis for ZBP-89. Taken together, data for the first time implicate ZBP-89 as a regulator of Pdcd4 by binding to the basal promoter either alone or by interacting with Sp family members.
INTRODUCTION
Pdcd4 (programmed cell death 4) is an important novel tumour suppressor, inhibiting carcinogenesis, tumour progression, invasion and intravasation. Pdcd4 interacts with translation initiation factors, namely, the RNA helicase eIF4A (eukaryotic initiation factor 4A) and the scaffolding protein eIF4G, and is involved in the control of eukaryotic transcription and translation. The pdcd4 gene has originally been identified as a gene whose ex- Abbreviations used: AcH3, acetylated histone H3; 5-aza-dC, 5-aza-2-deoxycytidine; ChIP , chromatin immunoprecipitation; COX-2, cyclo-oxygenase 2; eIF, eukaryotic initiation factor; EMSA, electrophoretic mobility-shift assay; H3K4m3, histone H3 Lys 4 trimethylation; HCC, hepatocellular carcinoma; HDAC1, histone deacetylase 1; IL, interleukin; NF-Y, nuclear factor Y; Pdcd4, programmed cell death protein 4; RACE, rapid amplification of cDNA ends; RA, retinoic acid; RAR, retinoic acid receptor; RT-PCR, reverse transcription-PCR; RXR, retinoid X receptor; siRNA, small interfering RNA; Sp1, specificity protein 1; TSA, trichostatin A; ZBP-89, zinc-finger-binding protein 89 1 To whom correspondence should be addressed (email heike.allgayer@umm.de).
pression is strongly up-regulated during apoptosis in response to different inducers. Pdcd4 was cloned independently by different groups and the human gene is located at chromosome 10q24 [1] . In normal tissue, pdcd4 expression is ubiquitous and has been reported, for example, in small duct epithelial cells of the normal mammary gland [1, 2] , growth-suppressed human neuroendocrine pancreatic carcinoma cells [3] , normal human lung tissue [4] and senescent human fibroblasts [5] . Pdcd4 levels are elevated in human IL-12 (interleukin 12)-induced NK (natural killer) and T-cells [6] , in acute myeloid leukaemia cells during granulocyte differentiation [7] , and a high expression was found in the suprabasal layer of the epidermis and suprabulbar area of the hair follicle [8] , indicating a role of Pdcd4 during differentiation. In several cancers, Pdcd4 expression is down-regulated, such as in lung-and renal-derived tumours [9] , tongue tumours [10] , hepatoma tissue [11] , invasive ductal breast carcinoma [12] , skin cancer [8] , human glioma [13] , nasopharyngeal carcinoma [14] , colorectal cancer [15] and HCC (hepatocellular carcinoma) [16] . Furthermore, the expression of Pdcd4 is regulated by drugs with anticancer effects such as topoisomerase inhibitors, COX-2 (cyclo-oxygenase 2) inhibitors, Herceptin, and RAR (retinoic acid receptor) agonists. Moreover, recent studies by us and others identified Pdcd4 as a target of miR-21 (microRNA- 21) and showed that the expression of Pdcd4 seems to be regulated in part at the translational level [17, 18] . However, little is known about the gene promoter and cognate transcription factors that mediate pdcd4 gene expression. So far, only a few studies were undertaken to find potential cis-regulatory elements and investigate their influence on pdcd4 gene transcription. In one initial study, the structure of the mouse gene was characterized. It was shown that the gene spanned approximately 21 kb, including 11 exons, and presented in a single copy [19] . The putative transcriptional start site was located 192 bp upstream from the translational start site, harbouring a TATA sequence and CAAT box at positions − 21 and − 81 respectively. Furthermore, putative binding sites for NF-κB (nuclear factor κB) at position − 488 to − 470 and two C/EBP (CCAAT/enhancer-binding protein)-binding sites ( − 424 to − 416 and − 254 to − 246) were found. For the chicken pdcd4 promoter, it was demonstrated that the transcription factor v-Myb was able to induce pdcd4 transcription [20] , and a knockout of c-Myb reduced pdcd4 levels [21] . Recently, it was shown that epigenetic mechanisms, such as DNA methylation, might also contribute to pdcd4 regulation. By knocking down DNA methyltransferase 1 in a hepatocellular carcinoma cell line, it was verified that demethylation of DNA-induced pdcd4 expression [22] , even through a demethylating agent resulted in no change in Pdcd4 amounts in breast cancer cell lines [12] . In addition, pdcd4 5 -CpG island methylation within the promoter was associated with reduced Pdcd4 mRNA in human glioma cell lines and tissue, and a restoration of pdcd4 was observed after blocking methylation in glioma cells [23] .
Zinc finger transcription factors play key roles in cell differentiation, motility, proliferation and survival. ZBP-89 (zinc-fingerbinding protein-89; also known as BFCOL1, BERF-1 and ZNF-148) is a Krüppel-type zinc-finger transcription factor that binds to the same GC-rich sequences as Sp1 or Sp3 [24] . It was cloned by screening of an expression library, with a GC-rich epidermal growth factor responsive element from the gastrin promoter [25] . Having bifunctional regulatory domains, ZBP-89 can activate or repress transcription of a variety of genes. It is known that ZBP-89 can repress the expression of vimentin [26] , ENA-78 (epithelial neutrophil-activating peptide-78) [27] , β2-integrin CD11b [28] , gastrin [29] , ODC (ornithine decarboxylase) [30] , SOX18 [31] , p16 [32] , Pax7 [33] and bovine adrenodoxin [24] . In contrast, it activates the expression of p21waf1 [34] , the T-cell α-and β-receptor [35] , the lymphocyte-specific protein-tyrosine kinase (lck) [36] , type 1 collagen [37] , IAP (intestinal alkaline phosphatase) [38] , GHR (growth hormone receptor) [39] and stromelysin [40] . So far, the exact mechanism as to how ZBP-89 exactly exercises these effects is still under investigation. It is widely believed that whether ZBP-89 binding stimulates or inhibits gene transcription depends on the specific promoter and perhaps other, as yet unidentified, factors. It can directly inhibit transcription, as in the case of the gastrin gene [29] , indirectly inhibit transcription through competition with Sp1 for binding to overlapping binding sites [30] , or through blocking the activity of Sp1 by proteinprotein interaction [26] . Moreover, ZBP-89 is usually overexpressed in human cancer cells, where it can efficiently induce apoptosis through p53-dependent and -independent mechanisms [41, 42] . Therefore, ZBP-89 may be interesting as a potential target in cancer therapy.
In consequence, the present study was undertaken (i) to for the first time characterize the core promoter of the human pdcd4 gene encoding this important tumour suppressor and (ii) to delineate major transcription factors and cis-elements by which transcriptional regulation is mediated. Taken together, we identified the transcriptional start sites of the human pdcd4 promoter, a functional CCAAT-box, and the basal promoter region spanning 548 bp upstream of the first exon. Furthermore, we show first evidence for Sp family transcription factors and especially ZBP-89 as important regulators for the transcription of the pdcd4 gene in solid cancers.
MATERIALS AND METHODS

Materials, antibodies and cell lines
Media/FBS (fetal bovine serum) were purchased from Invitrogen/Gibco and Sigma. All cell lines were obtained from the A.T.C.C. The following antibodies were from Santa Cruz: Sp1 (sc-59X), Sp2 (sc-643X), Sp3 (sc-644X), Sp4 (sc-654X), ZBP-89 (sc-48811X), trimethyl histone H4 (sc-134216), pan-acetyl (sc-8663), NF-YB (nuclear factor YB; sc-7711X) and unspecific IgG. The Anti-Xpress TM antibody was purchased from Invitrogen. Oligonucleotides were supplied by Metabion and are listed in and 2. Mithramycin and 5-aza-dC (5-aza-2-deoxycytidine) were from Sigma. or a non-silencing control (No. 4611G; Ambion). Experiments such as luciferase assays were performed at least in triplicate, after separate and independent transient transfections with at least 85 % transfection efficiency. Luciferase assays were performed on 96 well plates, using 150 ng of pdcd4-luciferase constructs or pGL3-basic vector together with 50 ng of Renilla luciferase plasmid. Alternatively, 100 ng of pdcd4-luciferase constructs or pGL3-basic vector and 10 ng of Renilla luciferase plasmid was used together with 150 ng of expression plasmid. The primers used are shown in Supplementary Table S1 (at http://www.bioscirep.org/bsr/032/bsr0320281add.htm) Nuclear extracts, EMSA (electrophoretic mobility-shift assay) and ChIP (chromatin immunoprecipitation)
Preparation of nuclear extracts and EMSAs was done as described in [43] , using oligonucleotides spanning regions + 2/ + 42, − 223/ − 185, − 170/ − 131 and − 88/ − 51 of the pdcd4 promoter. ChIP assays were performed using the ChIP assay kit from Upstate. Protein-DNA complexes were immunoprecipitated with 2 μg of trimethyl histone H4, pan-acetyl, NF-Y (nuclear factor Y), Sp-1, Sp-2, Sp-3, Sp-4 and ZBP-89 antibodies. DNA was purified and eluted with 100 μl of elution buffer using the Qiagen reaction purification kit and quantitative PCR amplification was done using 2 μl of DNA sample with primers amplifying region − 241/ − 42 of the pdcd4 promoter for 30 cycles using SYBR ® Green PCR Mastermix (Applied Biosystems). As a negative control, a region within the pdcd4 promoter region − 3495/ − 3294 was amplified for 35 cycles. Amplification of soluble chromatin prior to immunoprecipitation was used as an input control. The oligonucleotides used in the EMSA and ChIP assays are shown in Supplementary Table S2 (at http://www.bioscirep.org/bsr/032/bsr0320281add.htm).
Total RNA extraction, cDNA synthesis and real-time-PCR Total RNA from cell lines was extracted using the RNeasy Mini Kit (Qiagen), and total RNA from tissue specimen using TRIzol ® Reagent (Invitrogen). For real-time PCR, 500 ng of total RNA was reverse-transcribed in a total volume of 25 μl using oligodT. The cDNA was diluted 1:10, and 5 μl was used for quantification with the TaqMan Gene Expression Assay for ZBP-89 (Hs00222661_m1) or Pdcd4 (Hs00377253_m1). The human β-actin (ACTB) TaqMan assay served as an internal control.
RACE (rapid amplification of cDNA ends)
5 -RACE was performed using the SMART RACE cDNA Amplification Kit (Clontech) as described by the manufacturer's protocol, to identify the transcriptional start site of the pdcd4 gene. The 5 -RACE ready first-strand cDNA was synthesized using 1 μg of total RNA from MCF-7 cells and human placenta. The 5 -flanking sequence of pdcd4 was amplified using a universal primer (UMP, Clontech) and a pdcd4-specific primer located within exon 3 (see Supplementary Table S2 ). The resulting PCR products were gel-purified, cloned into the pGEM-T easy vector (Promega), and 20 different positive clones of each were sequenced.
5-Aza-dC treatment
A total of 4×10 5 cells were plated in a six-well plate in their respective medium supplemented with 10 % (v/v) FBS, and allowed to grow for 24 h. Cells were treated either with a final concentration of 10 μM 5-aza-dC for 72 h, changing the drug every 24 h, or with normal growth medium as a control. For expression analysis, cells were washed with ice-cold PBS, and total RNA or protein was isolated.
Preparation of reporter constructs
A 4042 bp regulatory region 3826 bp upstream from the major translational start site, including the first exon, of the pdcd4 gene (NCBI Reference Sequence: NT_030059.13) was amplified by PCR from human genomic DNA and cloned into pGL3-Basic (Promega) using KpnI and XhoI, to generate the pdcd4-luciferase reporter plasmid. A series of different 5 truncated fragments were created by PCR amplification from the approximately 4 kb reporter plasmid, and inserted into pGL3-Basic as described above. Site-directed mutagenesis was performed with the QuikChange ® kit (Stratagene) using the − 345/ + 355 and − 55/ + 355 reporter plasmids as templates. The site-specific mutations were confirmed by sequencing.
Expression vectors and construction of ZBP-89 expression plasmids
Expression vectors containing human Sp1 or Sp3 (pCMVSp1/Sp3) were gifts from Dr Guntram Suske (Institut für Molekularbiologie und Tumorforschung, Philipps-University Marburg, Marburg, Germany). cDNA for ZBP-89 was amplified by PCR (forward:
5 -GAACTCGAGATGAACATTGACGACAAAC-TGG-3 ; reverse: 5 -GAATCTAGATTAGCCAAAAGTC-TGGCCAGT-3 ) from MCF-7 cDNA and cloned into pcDNA6HisC (Invitrogen) using XhoI and XbaI. The identity of the inserts was confirmed by sequencing.
Statistical analysis
Statistical analysis was performed using SPSS version 14.0. To determine correlations between variables, Spearman's correlation coefficient was calculated; a P-value < 0.05 was considered significant.
RESULTS
Mapping of the pdcd4 transcriptional start site(s) and functional analysis of the promoter region
To identify the transcription initiation site(s) for pdcd4, 5 -RACE was performed using a pdcd4-specific primer anchored within exon 4, with total RNA from MCF-7 cells as well as from human placenta. 5 -RACE amplification from RNA of both samples resulted in an amplicon with an approximate size of 570 bp ( Figure 1A , lanes 2 and 3). Cloning and sequencing of these PCR products revealed multiple 5 -start sites, with the majority of clones including a region of 40 bp in exon 1, implicating the major transcriptional start site. A diagrammatic representation of the nucleotide sequence of the 5 region of the human pdcd4 gene including the first exon with the major transcription start site is given in Figure 1 (B). To define the minimal pdcd4 promoter region, and to identify putative cis-elements that regulate constitutive expression of pdcd4, we generated a series of 5 -pdcd4 promoter deletion constructs and transfected them into RKO, MCF-7 and HCT-116 cells. ( Figure 1B ). In addition, a CCAAT box at position + 19 to + 23, and an RAR/RXR (retinoid X receptor) inducible element at position + 26 were predicted ( Figure 1B ).
Histone modifications associated with the basal pdcd4 promoter region
Promoters of transcribed genes are enriched with K4 trimethylation and hyperacetylation on the N-terminal tail of histone H3. Amounts of modified histones H3K4me3 (histone H3 Lys 4 trimethylation) and AcH3 (acetylated histone H3) have been shown to correlate positively with the level of transcription. For pdcd4, it was recently shown that 5 CpG island methylation blocks Pdcd4 expression at the mRNA level [23] . In silico analysis of the promoter revealed a GC-rich region ( − 241/ − 41) within the core promoter with 12 CpG sites within the region of the putative zinc finger transcription factor binding sites. To clarify the role of epigenetic suppression of the pdcd4 gene, we first examined pdcd4 expression upon treatment with the DNA methyltransferase inhibitor 5-aza-dC. As shown in Figure 2 (A), the inhibitor led to an increase in Pdcd4 mRNA and protein. To further investigate local histone acetylation and H3 methylation in the chromatin associated with the basal pdcd4 promoter region, a ChIP assay was performed. The histone-associated DNAs, immunoprecipitated with antibodies against AcH3 and H3K4me3, were individually amplified with two primer sets covering the GC-rich basal promoter region, and an unspecific region approximately 3 kb upstream of the transcriptional start sites. In treated RKO cells, representing the situation with an unmethylated promoter, levels of H3K4me3 and AcH3 were higher as compared with the untreated control cells ( Figures 2B and 2C ). This pattern of histone modification is known to mark an open chromatin structure associated with active gene expression [44] . Our results indicate that the histone modifications at the basal pdcd4 promoter region are strongly associated with pdcd4 gene expression.
A CCAAT box is required for pdcd4 promoter activity and is competent to bind NF-Y In order to confirm that the putative CCAAT box at + 19 to + 23 shows a specific binding, we generated oligonucleotide probes spanning this site, and the corresponding mutated or deleted probes, and performed EMSA analysis. Unlabelled probe abolished the shifting of all bands except for one unspecific band. In contrast, competition with unlabelled oligonucleotides, with either a mutation or deletion of the CCAAT sequence, showed a shift of three bands, indicating a specific binding at this ciselement ( Figure 2F , left panel). The fact that NF-Y specifically binds CCAAT sequences in many eukaryotic genes prompted us to determine whether this element is also bound by NF-Y.
Comparison of the pdcd4 gene CCAAT box and its flanking sequences with the NF-Y-consensus showed only one mismatch (C/G to A). Therefore, a supershift analysis was conducted to investigate whether NF-Y transcription factors can bind to that CAAT-box using an antibody against the NF-YB subunit of the NF-Y trimeric complex. Addition of the antibody resulted in a single supershifted band demonstrating that NF-Y specifically binds the CCAAT box at position + 19 to + 23 ( Figure 2F , right panel). This was confirmed in a ChIP analysis for the same region, in which a clear increase in NF-Y binding to the natural pdcd4 promoter motif was observed ( Figure 2G ). To test the functional relevance of the CCAAT box, reporter constructs containing mutations or a deletion at this site were constructed. The wild-type sequence and the mutation or deletion are presented in Figure 2 (D). Transient transfection of the different reporter constructs into MCF-7 cells revealed that mutagenesis of the site at + 19/ + 23 resulted in a more than 60 % loss in reporter activity. The deletion led to a loss of 50 % ( Figure 2E ). Taken together, these data show functionality of the pdcd4-CCAAT-box which is bound by NF-Y.
Mithramycin represses pdcd4 promoter activity and decreases pdcd4 mRNA and protein amounts
Because the initial computer-based screen for cis-elements within the active basal promoter region revealed different potential zincfinger-binding motifs, we further investigated the functional relevance of zinc finger transcription factors for pdcd4-gene expression. Towards this end, cells were treated with mithramycin, which binds to GC-rich DNA sequences and impedes the binding of GC-specific transcription factors by steric hindrance. Cells were transfected with the reporter construct containing the active basal promoter region and treated with 50 nM mithramycin. Mithramycin decreased pdcd4 promoter activity by more than 50 % ( Figure 3A ). To confirm an effect of mithramycin on pdcd4 gene expression, cells were treated with 50 nM mithramycin for 24 and 48 h. As shown in Figures 3(B) and 3(C), the inhibition of zinc finger transcription factor binding led to a significant decrease in Pdcd4 mRNA and protein in all three cell lines. These observations support our hypothesis that the GC-rich and zinc-finger-binding sequences identified within the basal promoter are required for Pdcd4 expression.
Sp sites are functionally relevant for pdcd4 basal promoter activity Sp family transcription factors are ubiquitously expressed and represent zinc finger-containing DNA-binding proteins. They bind GC-rich motifs with high affinity and can regulate the expression of TATA-containing and TATA-less genes via proteinprotein interactions, or interplay with other transcription factors and/or components of the basal transcriptional machinery [45] . On the basis of the finding of different potential Sp-binding sites within the basal promoter region at positions − 195, − 162, − 147, − 86 and − 76, we asked to what extent these factors are required for pdcd4 gene expression. To show that all Sp sites are relevant for basic pdcd4 promoter activity, we transiently transfected the wild-type reporter construct spanning the active basal promoter region (pGl3del1_500), or a mutated reporter construct (pGl3del1_5004xmt) into RKO, HCT-116 and MCF-7 cells. The reporter assays revealed that mutation of four sites resulted in a 59 % (RKO), 57 % (HCT-116) or 50 % (MCF-7) loss in reporter Pdcd4 promoter activity and expression is repressed by mithramycin (A) Mithramycin represses the activity of the basal promoter region of pdcd4. Then 150 ng of pdcd4-luciferase constructs or pGL3-basic vector together with 50 ng of Renilla luciferase plasmid were transiently transfected into the cells, and 6 h post-transfection cells were mock-treated or treated with 50 nM mithramycin. The firefly luciferase activity was normalized with Renilla luciferase activity. The results are presented as the means + − S.D. from three independent experiments performed in quadruplicate. (B) Mithramycin treatment leads to a decreased Pdcd4 mRNA level. Total RNA was extracted, reverse-transcribed and quantified by real-time PCR using specific TaqMan primers and probes for Pdcd4. Samples were analysed in quadruplicate, and relative pdcd4 expression normalized against β-actin. Pdcd4 amounts are shown as a relative quantification, with cells that were either mock-treated or treated with 50 nM mithramycin. (C) Mithramycin treatment decreases Pdcd4 protein. Pdcd4 protein amounts were analysed by using anti-Pdcd4 antibody and equal amounts of protein were confirmed using an anti-β-actin antibody.
activity as compared with the wild-type construct ( Figure 4A ). Gel-shift and supershift analysis was conducted to investigate whether Sp transcription factors can bind to the basal promoter region, and to differentiate individual Sp family members bound to this region. Nuclear extracts of cells were incubated with three different probes (del713_6, del713_8 and del713_11) spanning the above described Sp-binding sites. As shown in Figure 4(B) , a 100-fold excess of unlabelled probe abolished the shifting of all bands, indicating a specific binding of transcription factors within all three oligonucleotides (lanes 1, 2, 8, 9, 15 and 16) . In supershift analysis, especially Sp1 (lanes 7, 19 and 17), in addition to Sp3 (lanes 12 and 19) and Sp4 (lane 20), was identified as the major Sp family protein bound to this region. To gain further evidence for Sp1 or Sp3 being essential for promoter activity, RKO cells were transiently co-transfected with the wildtype reporter construct spanning the active basal promoter region (pGl3del1_500), and either an expression plasmid for Sp1 or Sp3 (pCMV-Sp1 and pCMVSp3). Both Sp1 and Sp3 strongly induced pdcd4 promoter activity [Sp1 176 % (RKO), 17 % (HCT-116), 45 % (MCF-7); Sp3 193 % (RKO), 84 % (HCT-116), 59 % (MCF-7)], suggesting that either of these transcription factors alone can positively drive pdcd4 gene expression ( Figure 4C ). Since these data implicated Sp1 or Sp3 as possible transcription factors mediating pdcd4 gene expression at these promoter motifs, cDNA and cell lysates from cells overexpressing Sp1 or Sp3 and vector transfected cells were compared for Pdcd4 mRNA and protein amounts. In Sp1 or Sp3 transfected RKO cells, only the amount of endogenous Pdcd4 mRNA was noticeably higher than in vector-transfected cells, whereas endogenous Pdcd4 mRNA remained unaffected in HCT-116 and MCF-7 cells ( Figure 4D ). * Indicates supershifted bands, lower # indicates bands competed by the antibody. Overexpression of Sp1 and Sp3 induces Pdcd4 promoter activity and increases Pdcd4 mRNA, but is not sufficient to enhance Pdcd4 protein amounts. (C) The firefly luciferase activity was normalized with Renilla luciferase activity. Mock-vector-co-transfected luciferase activity was set to 100 %, and activity of the other constructs was calculated and plotted as a percentage of this value. The results are presented as the means + − S.D. from three independent experiments performed in quadruplicates. (D) Total RNA from cells transfected with the Sp1-, Sp3-or empty-expression plasmid was extracted, reverse transcribed and quantified by real-time PCR using specific TaqMan primers and probes for Pdcd4. Samples were analysed in quadruplicate, and relative Pdcd4 expression levels normalized against β-actin. Pdcd4 amounts are shown as a relative quantification, with untreated cells as a reference. (E) Cells were transfected in a six-well plate with 4 μg of pCMV-Sp1, pCMV-Sp3, the empty vector (ev) or (F) with a siRNA targeting Sp1, with scRNA used as a control. After 48 h post-transfection, cells were harvested and cell lysates were immunoblotted. Sp1, Sp3 and Pdcd4 protein amounts were analysed by using anti-Sp1, Sp3 or Pdcd4 antibody and equal amounts of protein were confirmed using an anti β-actin antibody.
This observation was paralleled by the absence of an influence of Sp1 or Sp3 overexpression on the Pdcd4 protein level in all three cell lines ( Figure 4E ). Owing to the high endogenous Sp1 expression in all cell lines examined, we performed additional knockdown experiments. As shown in Figure 4 (F), expression of a siRNA oligonucleotide against Sp1 decreased endogenous Sp1 protein to almost 55 % in RKO, to 55 % in HCT-116 and 51 % in MCF-7 cells respectively, but had little effect (∼ 4 %) on Pdcd4 protein in these cells. This led us to the assumption that Sp1 or Sp3 alone are not sufficient to regulate Pdcd4.
Expression of Pdcd4 and ZBP-89 correlate in different cell lines and basal pdcd4 promoter activity is induced by ZBP-89
The zinc finger transcription factor ZBP-89 has been implicated in the induction of growth arrest and apoptosis [41] . Furthermore, it can interact with Sp family members and HDAC1 (histone deacetylase 1) to regulate gene expression, and we found several potential binding sites within the basal promoter region of the pdcd4 gene ( Figure 1B Figure 5A) . A significant positive correlation (c = 0.76) between pdcd4 mRNA and zbp-89-mRNA was observed in these 17 cell lines (P = 0.001) ( Figure 5A ). As shown by the TRANSFAC database search and the previous results, the basal pdcd4 promoter region contains different Sp and ZBP-89-binding sites. To explore the possibility that the promoter activity to a major extent is regulated by ZBP-89, the activity of the luciferase construct driven by the basal promoter region in which all four Sp sites were mutated (pGLdel15004xmt) was measured after transient overexpression of ZBP-89. As can be seen ( Figure 5B), the activity of this promoter construct was still inducible by ZBP-89, leading us to the assumption that, additionally to Sp1 and Sp3, ZBP-89 is able to enhance pdcd4 gene expression. These observations were further supported by mithramycin inhibition of cells transiently transfected with the reporter construct containing the active basal promoter region, together with either the empty expression vector or the ZBP-89 expression construct ( Figure 5C ).
ZBP-89 binds to the pdcd4 basal promoter region
Based on the previous findings, we investigated whether ZBP-89 binds to the predicted sites within the pdcd4 promoter. Gelshift and supershift analysis was conducted using radiolabelled oligonucleotides (del713_6 and del713_8) spanning the ZBP-89-binding sites at positions − 208, − 154 and − 127, and nuclear extracts of the colon carcinoma cell line HCT-116. As shown in Figure 5 (E), binding of specific proteins was considerably higher for both oligonucleotides in ZBP-89 transfectants (lanes 1, 5, 9 and 13). Supershift analysis using a specific antibody recognizing the Xpress-Tag of the pcDNA6HisC construct specifically shifted (lanes 5 and 7) or blocked (lanes 13 and 15) a specific band as compared with the IgG control (lanes 8 and 16) after overexpression of ZBP-89. These results support the notion that ZBP-89-transcription factors are bound to the basal pdcd4 promoter region.
In vivo evidence for the physical interaction of ZBP-89 with the natural pdcd4 promoter
Gel-shift analysis had implicated different zinc-finger transcription factors bound to oligonucleotides corresponding to the basal region of the pdcd4 promoter. To determine which transcription factors bind to this region of the natural pdcd4 promoter, we performed ChIP analysis, using anti-Sp1, -Sp2, -Sp3, -Sp4 and -ZBP-89 antibodies. Quantitative PCR amplification of the immunoprecipitated DNA using the primers specific for region − 241/ − 42, identified ZBP-89 as the main endogenous binding partner to this natural promoter region, as compared with Sp1, Sp2, Sp3 and Sp4 ( Figure 5D ). The relative quantity of Sp transcription factors bound to the natural promoter region reflects the data in previous gel-shift analysis, where mainly Sp1 and, to some extent, Sp3 was found ( Figure 4B ). These results confirm that, in vivo, Sp1, Sp3 and ZBP-89 bind to the pdcd4 promoter, supporting the role of ZBP-89 as the main regulator within this basal promoter region.
ZBP-89 is a potent regulator of pdcd4 promoter activity and gene expression
The results from EMSA, supershift and ChIP assay demonstrate that ZBP-89 predominantly binds to the pdcd4 promoter. To confirm a decisive function of ZBP-89 for the expression of Pdcd4, we performed overexpression and knockdown experiments with ZBP-89 in RKO, HCT-116 and MCF-7 cells. Overexpression of ZBP-89 led to a significant increase (100-150 %) in pdcd4-basal promoter activity compared with the vector control ( Figure 6A ). This observation was further supported by the fact that the mRNA level of Pdcd4 was increased 200-250 % after 24 h for RKO and HCT-116 and after 48 h for MCF-7 respectively ( Figure 6B ). To gain evidence that ZBP-89-driven pdcd4 gene expression is relevant at the protein level, Western blot analysis was performed for ZBP-89, Pdcd4 and β-actin as internal control. In contrast with Sp1 and Sp3 ( Figures 4E and 4F (Figures 6D-6F ). Expression of a siRNA against ZBP-89 lowered the activity of the basal pdcd4 promoter by almost 60 % compared with scrambled siRNA (Figure 6D ). In addition, we also observed a 30-50 % reduction in endogenous Pdcd4 mRNA in cells transfected with ZBP-89 siRNA, as compared with control cells transfected with scrambled siRNA (Figure 6E ), suggesting that ZBP-89 significantly regulates pdcd4 gene expression in these cell lines. Additionally, we were interested to ascertain if the observed increase in basal pdcd4 promoter activity after ZBP-89 expression can be affected by NF-Y binding by the CCAAT-box. As can be seen (Figure 7A ), the activity of the promoter construct mutated at + 19/ + 23 was still inducible by ZBP-89 (>200 %) and enhanced compared with the wild-type CAAT box (>120 %), leading us to the assumption that ZBP-89 has no influence on the CCAA-box activity. We further investigated the binding of acetylated histones to the . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . basal pdcd4 promoter region after ZBP-89 expression, because recent studies have shown that ZBP-89 can function as a repressor of the vimentin and p16 promoter by recruiting histone deacetyase [32, 46] . To support our observations and to exclude the possibility that ZBP-89 is a suppressor related to our promoter, a ChIP assay was performed ( Figure 7B ). Based on the observation that overexpression of ZBP-89 resulted in a high amount of ZBP-89 protein in MCF-7 cells (Figure 6C ), we overexpressed ZBP-89 in this cell line and immunoprecipitated with antibodies against AcH3 and ZBP-89. The results in Figure 7 (B) show a higher binding of ZBP-89 after overexpression, accompanied by an increase (>200 %) in the binding of acetylated histones, which is commonly seen in genes that are being actively transcribed into RNA and supporting the notion that ZBP-89 is indeed an activator of pdcd4 promoter activity. Finally, we investigated the effect of 5-aza-dC on ZBP-89-induced pdcd4 gene expression. Towards this end, we examined Pdcd4 mRNA expression upon treatment with the DNA methyltransferase inhibitor 5-aza-dC either with overexpression of ZBP-89, or the empty vector. In line with the previous results, as shown in Figure 6 (C), the inhibitor led to an increase (230 %) of Pdcd4 mRNA after treatment with 5-aza-dC in HCT-116 cells transfected with the empty vector. A similar increase (200 %) was observed for the cells overexpressing ZBP-89. Interestingly, the combination of 5-aza-dC treatment upon ZBP-89 overexpression led to a significant increase (600 %) compared with the untreated cells. These results support the notion that ZBP-89 indeed is bound to the pdcd4 promoter, leading to enhanced pdcd4 gene expression, and confirm the data that the histone modifications at the basal pdcd4 promoter region are strongly associated with the accessibility for transcription factors like ZBP-89.
DISCUSSION
Pdcd4 is expressed ubiquitously in normal tissue and was initially identified as a gene that is up-regulated during apoptosis after treatment of cells with different pro-apoptotic substances [47] . In addition, there is accumulating evidence that the relative abundance of Pdcd4 expression is critical in cancer development. Accordingly, down-regulation of Pdcd4 was discovered in a variety of tumours and was associated with poor prognosis [48] . The important role of Pdcd4 as a tumour suppressor is further supported by studies showing an induction in the expression of this protein by drugs with anticancer effects [49, 50] . Since the microRNA miR-21 was discovered as a translational regulator of Pdcd4, and phosphorylation of Pdcd4 protein has been implicated to be accompanied by proteasomal degradation, we know how this molecule can be modulated at the translational and protein level [17, 51] . However, the transcriptional regulation of Pdcd4 has not yet been described systematically. So far, only the mouse pdcd4 promoter was characterized in silico, and a potential transcriptional start site, TATA sequence and a CCAAT box have been described. Additionally, a region that participated in the response to camtothecin has been elucidated [19] . Furthermore, the transcription factor v-Myb has been shown to be important for the induction of the chicken promoter [20] . In our present study, for the first time, we identified and characterized the human pdcd4 promoter and its activity. Through a series of deletion studies, we identified a GC-rich core promoter, which is sufficient to confer high-level activity to a luciferase reporter gene, mapping in the 5 -flanking region between − 345 and − 55 upstream of the first exon. In addition, we revealed several putative binding sites for transcription factors of the Sp family and ZBP-89 within this region. Interestingly, a fragment spanning the regions − 2253/ − 1999 showed the highest luciferase activity. We confirmed the existence of multiple transcriptional start sites within the first exon, and a functional CCAAT box at + 19/ + 23. EMSA and ChIP analysis proved the binding of NF-Y, a transcription factor usually bound to active CCAAT boxes. Functionality of the CCAAT box was further supported by mutation or deletion of this specific element, leading to lower promoter activity.
In the present study, we also found that histone modifications within the basal promoter region contribute to the expression of the pdcd4 gene. Genes can be regulated at the transcriptional level as well as through epigenetic modifications. One common phenomenon in cancer cells is DNA methylation within the promoter of tumour suppressor genes. It results in transcriptional silencing of these genes and promotes tumour development. For pdcd4, it was recently shown that methylation modifies mRNA expression in a hepatocellular cell line and human glioma cells [22, 23] . Beyond that, modifications to histone proteins, such as methylation and acetylation, are thought to help keeping genes active or silent. Histone modification alters the status of open chromatin domains and thus affects gene transcription [44] . Our findings that, in RKO colorectal cancer cells, treatment with a DNA methyltransferase inhibitor leads to an up-regulation of mRNA and protein by inducing histone hyperacetylation and hypomethylation within the basal promoter region, are important for understanding how this gene is regulated at the epigenetic level.
expression plasmid were transiently transfected into the cells and 6 h post transfection, cells were mock-treated or treated with 50 nM mithramycin. The firefly luciferase activity was normalized with Renilla luciferase activity. The results are presented as the means + − S.D. from three independent experiments performed in quadruplicate. EMSA, supershift and ChIP demonstrating the in vitro and in vivo binding of ZBP-89 transcription factor to the pdcd4 promoter region. (D) The in vivo association of Sp1, Sp2, Sp3, Sp4 and ZBP-89 with the pdcd4 basal promoter was evaluated with ChIP assay in HCT-116 cells. Equal amounts of chromatin were incubated with the indicated antibodies and quantified by real-time PCR, using a primer set specific for the basal region. As a negative control, immunoprecipitated DNA was amplified by a primer set specific to an off-target region in the pdcd4 promoter. (E) Equal amounts of nuclear extract from vector-control HCT-116 cells and ZBP-89-transfected HCT-116 cells were incubated with two end-labelled oligonucleotides (del713_6 and del713_8) in the presence or absence of a 100-fold excess of the unlabelled competitor (Comp.) sequence, and the indicated antibody. EMSA was carried out using 10 μg of nuclear extract, 1 μg of poly(dI-dC) · (dI-dC) , 1×10 6 c.p.m. of 33 Sp family proteins and other Krüppel-like factor proteins regulate basal/constitutive expression of genes involved in multiple functions in both normal and cancerous tissues [52] . Genes that Equal amounts of chromatin were incubated with the indicated antibodies and quantified by real-time PCR, using a primer set specific for the basal region. As a negative control, immunoprecipitated DNA was amplified by a primer set specific to an off-target region in the pdcd4 promoter 4 kb upstream from the Pdcd4 transcriptional start site ( − 3495 to − 3294 bp). ZBP-89 induced pdcd4 promoter activity is enhanced by 5-aza-dC treatment. (C) HCT-116 cells were transiently transfected with ZBP-89 and treated with 5-aza-dC at a final concentration of 10 μM for 24 h and subjected to Q-PCR. Total RNA was extracted, reverse-transcribed and quantified by quantitative-PCR using specific TaqMan primers and probes for Pdcd4. Samples were analysed in quadruplicates, and relative Pdcd4 expression was normalized against β-actin. Pdcd4 amount is shown as a relative quantification (RQ), with untreated cells as a reference.
expression. Strategies for inhibiting such transcription factordependent pathways have focused on several approaches which include drugs that inactivate GC-rich DNA motifs. Mithramycin, a cell-permeable reagent, binds GC-rich motifs, and studies show that treatment of cells with this compound decreases DNA binding of transcription factors known to influence gene expression through interaction with GC-rich regions [52] . We therefore incubated cells with this drug and observed a reduced basal promoter activity and mRNA level leading to a completely abolished expression of Pdcd4 protein. Consistent with this observation, sequence analysis of the fragment − 345 to − 55 identified several consensus transcription factor binding sites for Sp family members at positions − 195, − 162, − 147, − 86 and − 76. Furthermore, mutation of all Sp sites decreased the pdcd4 promoter activity by 50 % in two colorectal and one breast cancer cell line and led us to the assumption that pdcd4 expression is influenced by Sp family members. This notion was supported by a study showing that pdcd4 is up-regulated by IL-12 [6] . IL-12, which has shown significant antitumour activity in several preclinical animal tumour models, led to an enhanced sensitivity to Fas-induced cell apoptosis through regulating the binding of transcription factors towards an NF-κB-Sp1 element in the Fas promoter [53] . Besides, it is known that the expression of Pdcd4 is up-regulated in senescent fibroblasts, a situation in which Sp1 also plays a pivotal role [5] . P16 is a tumour suppressor protein that has been widely proposed to mediate entrance of the cells into the senescent stage, and it was shown that an increase in Sp1-binding activity acts as a positive transcription regulatory element of the induction of p16 expression during cell aging [54] . Furthermore, it was shown that senescence-associated phosphorylated extracellular-signal-regulated protein kinases 1 and 2 enhanced p21 (Sdi1) transcription by phosphorylating Sp1 [55] .
However, even though we observed an endogenous binding of Sp1, Sp3 and to some extent Sp4 in EMSA and ChIP studies in parallel with an induction of pdcd4 promoter activity in all cell lines and an increased Pdcd4 mRNA in RKO, we failed to observe a regulation of Pdcd4 protein after overexpression or knockdown of Sp1 or Sp3. One possible explanation for this non-existent inducible protein expression could be the fact that Pdcd4 is tightly controlled at the translational level [17] . On the other hand, the activity of Sp1 and Sp3 at any specific promoter is governed by several variables, including the ratio of expression of Sp1 and Sp3, the expression and modification state of interacting proteins with which Sp1 or Sp3 form a complex, and variation in binding activities brought about by, for example post-translational modifications. Furthermore, the methylation around GC boxes is one way to regulate the DNA-binding activity of Sp1 and Sp3. Indeed we observed an induction of the pdcd4 promoter activity following demethylation. In contrast with the situation in senescent cells, where Sp1 is activated through phosphorylation, a recent study has linked the anti-angiogenic effects of celecoxib to the modulation of Sp1 transcription factor activity followed by inactivation of this transcription factor by phosphorylation [56] . Furthermore, COX-2 inhibitors decreased vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins [57] , whereas it was shown by other groups that pdcd4 expression is up-regulated through this inhibitor [50] .
As forced expression of Sp transcription factors induced pdcd4 promoter activity, but failed to regulate the Pdcd4 protein amounts, we investigated the importance of other transcription factors for full activation of the basal promoter region. Besides Sp-binding sites, within the basal promoter region at positions − 208, − 154 and − 127, we found cis-elements for another Krüppel-type zinc-finger transcription factor, ZBP-89. This observation prompted us to suggest the importance of ZBP-89 binding to its respective site for the activation of the pdcd4 gene. Originally, ZBP-89 was proposed to be ubiquitously expressed [25] . However, it is now apparent that ZBP-89 has been implicated in many cellular functions related to cancer, including cell growth, differentiation, transformation, myogenesis, haemopoiesis and senescence [58] . Furthermore, diverse studies have shown that ZBP-89 is elevated in some tumour tissues and cell lines, including gastric-, colorectal-, breast cancer, melanoma, HCC and in a variety of other gastrointestinal cancers [58] . This is important since Pdcd4 has been shown to act as an apoptotic factor [47, 50] , besides being a suppressor of malignant transformation [59,59a] , tumorigenesis, tumour progression [60] and cellular senescence [5] . However, the potential role of ZBP-89 in the transcriptional regulation of Pdcd4 has not been determined so far. In our study, overexpression of ZBP-89 was able to significantly induce basal pdcd4 promoter activity, even after mutation of all four Sp sites within the basal promoter region. Consistent with this observation, mithramycin treatment inhibited the DNA binding of ZBP-89 in all three cell lines examined. Moreover, EMSA and ChIP data showed the in vivo occupancy of the pdcd4 promoter with ZBP-89 as clear indicators for a role of especially ZBP-89 in the transcription of the pdcd4 gene. Most notably, ZBP-89 was the most prominent protein bound in ChIP compared to Sp1, 2, 3 or 4. It has been suggested that ZBP-89 can function through multiple mechanisms and can be either an activator or a repressor of a variety of genes. These mechanisms include the competition of ZBP-89 with transcription activators such as Sp1 for overlapping binding sites, thereby decreasing promoter activity and transcription intensity [61] . Others include the ability of ZBP-89 to recruit the co-activator p300 to the promoter of the target gene, resulting in an up-regulation of gene expression [41] . Finally, ZBP-89 is able to recruit a co-repressor to a specific promoter, and this co-repressor either negatively regulates other factors that are present, or alters the local chromatin structure [62] . Based on our results, the function of ZBP-89 towards the Pdcd4 promoter most likely is that of a transcriptional activator and potential tumour suppressor, potentially by interacting with other co-activators. This notion is supported by the fact that we found that histone modifications, such as the acetylation status of histone H3, within the basal promoter region contribute to the expression of the pdcd4 gene. This suggests that an alteration of the local histone structure influenced through ZBP-89 might be able to drive the expression of pdcd4. Consistent with these results, another study has investigated the mode of action of the HDAC inhibitor TSA (trichostatin A) on vimentin gene expression. They documented an increase in the acetylation status of histone H3 at the endogenous vimentin gene after TSA treatment. Interestingly, they found that recruitment of HDAC1 to the respective promoter was brought about via ZBP-89. Even though in this study ZBP-89 acted as a transcriptional repressor, we actually observed a higher binding of acetylated histones after ZBP-89 expression. Based on that, one could speculate that, in an analogous situation but different cellular background and gene-specific manner, ZBP-89 acts as a transcriptional activator or repressor.
In contrast with Sp1 or Sp3, we observed a significant induction or reduction of Pdcd4 mRNA and protein after overexpression, or knock down, of ZBP-89. Previous studies reported a regulation of Pdcd4 and ZBP-89 under similar experimental conditions. It was shown that under inflammatory conditions that can also contribute to the generation of a tumour-promoting environment by stromal cells, Pdcd4 and ZBP-89 were down-regulated in macrophages or fibroblasts [63,63a] . Furthermore, stimulation by RA (retinoic acid) resulted in increased expression of these proteins in breast cancer cells and HeLa cells [49, 64] and finally, Pdcd4 and ZBP-89 both seem to be enhancers of drug sensitivity [9, 65] . Additionally, overexpression of ZBP-89 can inhibit the proliferation of human stomach adenocarcinoma cells [66] . Regarding RA, we have also observed an enhanced pdcd4 promoter activity and elevated protein amounts of Pdcd4 in breast cancer cell lines after stimulation with all-trans RA (results not shown). This observation is supported by a study showing an enhanced Pdcd4 protein expression following RA treatment in breast cancer cell lines [67] . Consistent with those results, we found a cis-element downstream of the first exon of the pdcd4 promoter, which showed an enhanced binding of complexes after stimulation with all-trans RA. However, no influence on the binding of any transcription factors, including the zinc finger transcription factors examined in our present study, was observed after RA treatment in EMSA or ChIP within the basal promoter region, and the inducible cis-element identified was not bound by RAR or RXR.
Finally, various studies have shown that ectopic overexpression of ZBP-89 can enhance apoptosis and that ZBP-89, like Pdcd4, is inducible by different pro-apototic stimuli [41, 47, 49, 65, 68, 69] . However, the molecular mechanism leading to the inhibitory effect of ZBP-89 is largely unknown. Initial studies have shown that ZBP-89 overexpression stabilizes the p53 protein and enhances its transcriptional activity [42] . Later it was found that ZBP-89 also induces apoptosis through a p53-independent mechanism that requires JNK (c-Jun N-terminal kinase) [41] . Recently, it has been suggested that ZBP-89 can enhance tumour cell death through up-regulating the pro-apoptotic molecule Bak, a member of the Bcl-2 family in HCC cells [68] . These results supported an earlier study that demonstrated that ZBP-89 can significantly enhance the sensitivity of HCC cells to anti-tumour agents such as 5-fluorouracil, by increasing caspase-6 activity, G 2 /M-phase abrogation and S-phase arrest [65] . As mentioned, it has been suggested that Pdcd4 expression is increased during apoptosis in response to different inducers and it was shown for HCC that down-regulation of Pdcd4 by specific siRNAs weakened the sensitivity against 5-fluorouracil [70] . In addition, Pdcd4 was shown to be a pro-apototic molecule involved in TGFβ1 (transforming growth factor β1)-induced apoptosis in human HCC cells [69] , supporting the conclusion that Pdcd4 and ZBP-89 are potentially directly related in their function as tumour suppressors. Our findings on ZBP-89-mediated regulation of the pdcd4 promoter can also help us to understand how ZBP-89 accomplishes its pro-apoptotic role in many types of cancers.
In conclusion, this is the first study, to our knowledge, to characterize the human pdcd4 promoter. Our results clearly demonstrate that ZBP-89 is a potent trans-regulator, along with especially Sp1 and 3, for constitutive pdcd4 promoter activity. After further clarification of diverse translational and protein modifying mechanisms, our present results on the roles of Sp1, Sp3 and ZBP-89 in the regulation of the humane pdcd4 gene provide a basis for the understanding of the transcriptional regulation of this important tumour suppressor. Particularly since the role of ZBP-89 in cancer has been discussed ambivalently to date, our data support the role of ZBP-89 in inhibiting carcinogenesis. The observation that ZBP-89 as a regulator of Pdcd4 behaves as a tumour suppressor is in line with other studies investigating the role of ZBP-89 in cancer. Pdcd4 is, besides its well-characterized functions as a suppressor of transformation, translation and inducer of apoptosis, a potent suppressor of invasion and intravasation, the two decisive initial steps of the metastatic cascade. In consideration of these aspects, it is important to stress the role of ZBP-89 as a potent trans-regulator of Pdcd4.
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